Edodekin Alfa Uses, Dosage, Side Effects and more

Edodekin Alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery).

Trade Name Edodekin Alfa
Generic Edodekin alfa
Edodekin alfa Other Names Edodekin alfa, Human il-12 (recombinant), Interleukin 12 (human), Interleukin-12, human, Recombinant Human Interleukin-12, Recombinant interleukin-12
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Innovators Monograph

*** Taking medicines without doctor's advice can cause long-term problems.
Share